Al-Momen AK, Shaheen FAM, El-Aqeil NE, Sheikh IA, Braimo WA
Bezafibrate in the management of vascular access and
(Sep) 24:509-511 1995
Bezafibrate, a clofibrate analogue used in the treatment of hyperlipidemia,
also has effects on hemostasis, including a lowering of plasma fibrinogen
levels, enhancement of fibrinolysis, elevation of low ATIII levels, and
depression of platelet aggregability. Al-Momen and colleagues gave 200 mg
daily to 9 patients with frequent dialyzer clotting episodes and to 8 HD
patients without dialyzer clotting problems for four weeks. Fibrinogen
levels were decreased in both groups, from 4.7 to 2.6 g/L in the
clottingİprone group and from 4.0 to 2.5 g/L in controls. During the 4-week
follow-up period, there were no episodes of dialyzer clotting. Also, 3 of
the 9 patients had an access thrombosis during the 8 weeks preceding
bezafibrate therapy, and it is claimed that access clotting incidence was
reduced as well. However, any conclusions with regard to access thrombosis
are obviously overstated.
Comment: The findings are interesting with regard to dialyzer
clotting. This study was done using new dialyzers. It would be interesting
to see if the reuse number is increased in patients taking bezafibrate.
To go back use the BACK button on your browser.
Otherwise click on the desired link to this article below:
Basic hemodialysis :
Vascular Access: graft/fistula
CRF by problem area :